Gestalt Diagnostics And Deep Bio Announce Strategic Relationship To Deliver Image Analysis Algorithms within Gestalt’s Digital Pathology Platform

Gestalt Diagnostics and Deep Bio announced their strategic relationship on the development of an integrated workflow for pathologists to use Artificial Intelligence algorithms directly within Gestalt’s PathFlow® platform. Deep Bio’s algorithm analyzes whole slide images (WSIs) of H&E-stained prostate core needle biopsy tissue specimens to detect and classify prostate cancer. Using the PathFlow® platform, pathologists now have a superior support tool in diagnosing prostate cancer.

Recommended AI News: Actian Launches Next-Generation Zen Embedded Database For Mobile And IoT

“Optimizing the pathology workflow with an interoperable solution that combines the value of Gestalt’s full digital pathology platform and Deep Bio’s DeepDx® AI algorithms enables a high throughput diagnostic process,” says Gestalt COO & Chief Strategy Officer, Lisa-Jean Clifford. “Providing pathologists with instant access to AI algorithms directly within their workflow presents them with key data in real-time, shortening the time to diagnosis for cancer patients. We are excited to be collaborating with Deep Bio to provide pathology labs, and pathologists, with this superior solution.”

“Deep Bio’s relationship with Gestalt Diagnostics brings us one step closer to our vision of supporting pathologists and oncologists with timely and accurate diagnosis and prognosis, for better treatment decision-making. We believe our AI-powered DeepDx is a powerful addition to the seamless and integrated clinical workflow afforded by PathFlow”, said Deep Bio’s founder and CEO Sun Woo Kim.

Recommended AI News: TripleLift Names New Leadership to Oversee Technology Organization